ArticleJournal of the American Chemical Society2019
Mechanism of Inactivation of Ornithine Aminotransferase by (1
Article in Journal of the American Chemical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Single-cell analysis of TIGD genes in hepatocellular carcinoma: Prognostic value and functional characterization.Translational oncology · 2026Article
- Targeting Conformational Flexibility of a Reactive Intermediate to Enhance Selectivity of a GABA Aminotransferase Inactivator.Journal of the American Chemical Society · 2026Article
- Inactivation of ornithine aminotransferase by (1Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Molecular Basis of GABA Aminotransferase Inhibition in Epilepsy: Structure, Mechanisms, and Drug Development.Current issues in molecular biology · 2025Review
- Synthesis of (2The Journal of organic chemistry · 2024Article
- Design, Synthesis, and Mechanistic Studies of (ACS chemical biology · 2024Article
- FromiScience · 2024Article
- TP53 mutation-related senescence is an indicator of hepatocellular carcinoma patient outcomes from multiomics profiles.Smart medicine · 2023Article
- Structural and Mechanistic Basis for the Inactivation of Human Ornithine Aminotransferase by (3Molecules (Basel, Switzerland) · 2023Article
- Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.Journal of clinical laboratory analysis · 2022Article
- Determination of the pH dependence, substrate specificity, and turnovers of alternative substrates for human ornithine aminotransferase.The Journal of biological chemistry · 2022Article
- Rational Design, Synthesis, and Mechanism of (3Journal of the American Chemical Society · 2022Article
- Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.ACS medicinal chemistry letters · 2022Article
- Molecular determinants of etoposide resistance in HL60 cells.Bioinformation · 2022Article
- Turnover and Inactivation Mechanisms for (Journal of the American Chemical Society · 2021Article
- Remarkable and Unexpected Mechanism for (Journal of the American Chemical Society · 2021Article
- Chemical Aspects of Human and Environmental Overload with Fluorine.Chemical reviews · 2021Review
- Structural and Kinetic Analyses Reveal the Dual Inhibition Modes of Ornithine Aminotransferase by (1ACS chemical biology · 2021Article
- A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of γ-Aminobutyric Acid.Journal of the American Chemical Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The inhibition of ornithine aminotransferase (OAT), a pyridoxal 5'-phosphate-dependent enzyme, has been implicated as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, for which there is no effective treatment. From a previous evaluation of our aminotransferase inhibitors, (1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.